Serpins, the vasculature, and viral therapeutics - PubMed

Affiliations

• PMID: 16146796
• DOI: 10.2741/1862

Review

Serpins, the vasculature, and viral therapeutics

Jakob Richardson et al. Front Biosci. 2006.

Abstract

Serine protease inhibitors, termed serpins, are key regulators of numerous biological pathways that initiate inflammation, coagulation, angiogenesis, apoptosis, extra-cellular matrix composition and complement activation responses. Viruses have encoded serpins to guard themselves from host immune attack. The myxoma virus which infects rabbits secretes a highly potent anti-inflammatory serpin, Serp-1, which targets thrombolytic and thrombotic proteases as a means to fend off coagulation and inflammatory reactions to viral infection. These reactions act as a defense, produced by the host, to counter viral infection and invasion. When infused in animals after vascular injury, Serp-1 elicits exceptional anti-inflammatory activity, whereas the mammalian serpin, plasminogen activator inhibitor-1 (PAI-1), which also targets thrombotic and thrombolytic proteases can induce a pro-thrombotic response. During arterial injury, PAI-1 is highly expressed and increased PAI-1 concentration can result in acute thrombosis after aortic transplant in mouse models. The reactive center loop amino acid sequence is a fingerprint for serpin function and this function is highly sequence specific such that modification in this sequence can markedly alter activity. For instance, the alteration of the serpin reactive site loop P1-P1I amino acid sequence nullified the anti-inflammatory activity of Serp-1 and modification of P2-P7 initiated a pro-inflammatory response with vascular remodeling with aneurysm formation. Furthermore Serp-1 has demonstrated the capacity to utilize a mammalian serine protease receptor, the urokinase-type plasminogen activator receptor (uPAR), to alter cellular signaling in part through the actin binding protein cytoskeletal system (via filamin B). In this review, the molecular mechanisms relating inflammation and coagulation pathways to atherosclerosis and how the viral serpin, Serp-1, modifies these pathways in order to exhibit this profound anti-inflammatory activity without associated adverse thrombosis are discussed. Viral and vascular serpins targeting the thrombolytic cascade represent a potential new and untapped therapeutic resource.

Similar articles

• Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.

  Dai E, Viswanathan K, Sun YM, Li X, Liu LY, Togonu-Bickersteth B, Richardson J, Macaulay C, Nash P, Turner P, Nazarian SH, Moyer R, McFadden G, Lucas AR. Dai E, et al. J Biol Chem. 2006 Mar 24;281(12):8041-50. doi: 10.1074/jbc.M509454200. Epub 2006 Jan 9. J Biol Chem. 2006. PMID: 16407226

• Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury.

  Dai E, Guan H, Liu L, Little S, McFadden G, Vaziri S, Cao H, Ivanova IA, Bocksch L, Lucas A. Dai E, et al. J Biol Chem. 2003 May 16;278(20):18563-72. doi: 10.1074/jbc.M209683200. Epub 2003 Mar 10. J Biol Chem. 2003. PMID: 12637546

• Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.

  Viswanathan K, Liu L, Vaziri S, Dai E, Richardson J, Togonu-Bickersteth B, Vatsya P, Christov A, Lucas AR. Viswanathan K, et al. Thromb Haemost. 2006 Mar;95(3):499-510. doi: 10.1160/TH05-07-0492. Thromb Haemost. 2006. PMID: 16525579

• The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation.

  Chen H, Davids JA, Zheng D, Bryant M, Bot I, van Berckel TJ, Biessen E, Pepine C, Ryman K, Progulski-Fox A, Kesavalu L, Moyer R, McFadden G, Lucas A. Chen H, et al. Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):99-110. doi: 10.2174/1871529x11313020003. Cardiovasc Hematol Disord Drug Targets. 2013. PMID: 23987998 Review.

• Serpins for diagnosis and therapy in cancer.

  Zheng D, Chen H, Davids J, Bryant M, Lucas A. Zheng D, et al. Cardiovasc Hematol Disord Drug Targets. 2013 Aug;13(2):123-32. doi: 10.2174/1871529x11313020005. Cardiovasc Hematol Disord Drug Targets. 2013. PMID: 23988000 Review.

Cited by

• The current status and future directions of myxoma virus, a master in immune evasion.

  Spiesschaert B, McFadden G, Hermans K, Nauwynck H, Van de Walle GR. Spiesschaert B, et al. Vet Res. 2011 Jun 9;42(1):76. doi: 10.1186/1297-9716-42-76. Vet Res. 2011. PMID: 21658227 Free PMC article. Review.

• Salivary Exosome Proteomics and Bioinformatics Analysis in 7,12-Dimethylbenz[a]anthracene-Induced Oral Cancer with Radiation Therapy-A Syrian Golden Hamster Model.

  Wang WC, Huang MY, Chen YK, Lan WC, Shieh TM, Shih YH. Wang WC, et al. Diagnostics (Basel). 2021 Dec 28;12(1):65. doi: 10.3390/diagnostics12010065. Diagnostics (Basel). 2021. PMID: 35054231 Free PMC article.

• Comparative genomics of parasitic silkworm microsporidia reveal an association between genome expansion and host adaptation.

  Pan G, Xu J, Li T, Xia Q, Liu SL, Zhang G, Li S, Li C, Liu H, Yang L, Liu T, Zhang X, Wu Z, Fan W, Dang X, Xiang H, Tao M, Li Y, Hu J, Li Z, Lin L, Luo J, Geng L, Wang L, Long M, Wan Y, He N, Zhang Z, Lu C, Keeling PJ, Wang J, Xiang Z, Zhou Z. Pan G, et al. BMC Genomics. 2013 Mar 16;14:186. doi: 10.1186/1471-2164-14-186. BMC Genomics. 2013. PMID: 23496955 Free PMC article.

• Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease.

  Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Povero D, et al. PLoS One. 2014 Dec 3;9(12):e113651. doi: 10.1371/journal.pone.0113651. eCollection 2014. PLoS One. 2014. PMID: 25470250 Free PMC article.

• Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

  Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Vaisar T, et al. J Clin Invest. 2007 Mar;117(3):746-56. doi: 10.1172/JCI26206. J Clin Invest. 2007. PMID: 17332893 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal